23
Participants
Start Date
July 31, 2005
Primary Completion Date
August 31, 2011
Study Completion Date
August 31, 2013
Filgrastim
5 mcg/kg/day starting on Day 3 after each R-CVP cycle and on Day 6 after HiCy.
Rituximab
375 mg/m\^2 on Day 1 and Day 8 of each R-CVP cycle. 375 mg/m\^2 on Day -4 of HiCy and weekly for four weeks after HiCy.
Cyclophosphamide
1500 mg/m\^2 on Day 1 of each R-CVP cycle. 50 mg/kg/day on Days -3, -2, -1, and 0 of HiCy.
Cytarabine
100 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
Methotrexate
3 g/m\^2 on Day 8 of each cycle of R-CVP.
Prednisone
100 mg on Days 1-5 of each cycle of R-CVP.
Hydrocortisone
50 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
Vincristine
1.4 mg/m\^2 on Day 1 of each cycle of R-CVP.
Leucovorin
25 mg four times daily after methotrexate administration. Dosing continues until adequate methotrexate levels are reached.
Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
National Cancer Institute (NCI)
NIH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER